We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insulet's Q2 EPS rose 112.7% to $1.17, topping the consensus estimate by more than 25%.
PODD's Q2 revenues climbed 33% to $649.1M, led by strong U.S. and international Omnipod sales.
Insulet raised its 2025 CER revenue growth forecast to 24%-27%, with Omnipod growth at 25%-28%.
Insulet Corporation (PODD - Free Report) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.17, up 112.7% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 25.81%.
GAAP EPS was 32 cents compared with $2.59 in the prior-year period.
PODD’s Q2 Revenues
Revenues totaled $649.1 million, which beat the Zacks Consensus Estimate by 5.46%. The top line jumped 33% year over year and 31.4% at constant exchange rate or CER. CER growth exceeded the company’s high end of the guidance range of 26%.
Following the announcement on Aug. 7, PODD shares gained 1.2% to close at $307.10 on the Aug. 8 session.
PODD’s Q2 Segmental Revenues
Insulet’s total Omnipod revenues of $639 million reflected an increase of 33% year over year and 31.4% at CER. International Omnipod revenues of $185.8 million rose 45% (up 38.8% at CER). U.S. Omnipod revenues grew 28.7% year over year to $453.2 million.
Insulet Corporation Price, Consensus and EPS Surprise
The Drug Delivery business revenues totaled $10.2 million, highlighting an increase of 25.9% year over year.
Insulet’s Q2 Margin Performance
The gross profit in the reported quarter was $452.2 million, up 36.7% from the prior-year quarter’s figure. The gross margin of 69.7% expanded 193 basis points year over year.
Selling, general & administrative expenses rose 15.8% year over year to $257.7 million.
Research and development expenses jumped 36.2% year over year to $73.4 million.
The operating profit in the quarter totaled $121.1 million, up 122.2% from the year-ago reported actuals. The operating margin of 18.7% expanded 750 basis points year over year.
Insulet’s Cash Position
Insulet exited the second quarter of 2025 with cash and cash equivalents of $1.12 billion compared with $1.28 billion at the end of the first quarter.
Cumulative net cash provided by operating activities at the end of the second quarter was $260.3 million.
PODD’s 2025 Revenue Guidance
For 2025, the company now expects CER revenue growth to be 24%-27% (earlier 19%-22%). Insulet’s total Omnipod revenue growth is expected in the range of 25%-28% (previously 20% to 23%). The company expects Drug Delivery revenues to decline 30%-25% (earlier 35%-25%). The Zacks Consensus Estimate for the company’s 2025 revenues currently stands at $2.54 billion.
For the third quarter, Insulet projects revenue growth of 22%-25%. Total Omnipod revenues are also anticipated to grow 24-27%. Drug Delivery revenues are expected to decline 80%-75%. The consensus mark for the company’s third-quarter revenues currently stands at $666 million.
Our Take on Insulet’s Q2 Results
Insulet exited the second quarter of 2025 on a solid note, with both earnings and revenues beating estimates. The company grew new customer starts on a year-over-year and sequential basis in the United States for both type 1 and type 2, and internationally. U.S. Omnipod revenues benefited from a prior-year stocking dynamic and timing of rebates.
Internationally, growth in the U.K., Germany and France was particularly strong, in addition to other countries where Omnipod 5 was launched. The expansion of both margins in the quarter is highly encouraging. Insulet raised its full-year revenue guidance, making 2025 its tenth straight year of 20% or more growth on a constant-currency basis.
PODD’s Zacks Rank & Key Picks
PODD currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , GeneDx Holdings (WGS - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite’s 10.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 13.87%.
GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, exceeding the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%.
WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry’s 18.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 231.40%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a second-quarter 2025 adjusted EPS of 75 cents, which topped the Zacks Consensus Estimate by 4.2%.
BSX has a historical five-year earnings growth rate of 13.3% compared with the industry’s 2.7% growth. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 8.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
Key Takeaways
Insulet Corporation (PODD - Free Report) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.17, up 112.7% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 25.81%.
GAAP EPS was 32 cents compared with $2.59 in the prior-year period.
PODD’s Q2 Revenues
Revenues totaled $649.1 million, which beat the Zacks Consensus Estimate by 5.46%. The top line jumped 33% year over year and 31.4% at constant exchange rate or CER. CER growth exceeded the company’s high end of the guidance range of 26%.
Following the announcement on Aug. 7, PODD shares gained 1.2% to close at $307.10 on the Aug. 8 session.
PODD’s Q2 Segmental Revenues
Insulet’s total Omnipod revenues of $639 million reflected an increase of 33% year over year and 31.4% at CER. International Omnipod revenues of $185.8 million rose 45% (up 38.8% at CER). U.S. Omnipod revenues grew 28.7% year over year to $453.2 million.
Insulet Corporation Price, Consensus and EPS Surprise
Insulet Corporation price-consensus-eps-surprise-chart | Insulet Corporation Quote
The Drug Delivery business revenues totaled $10.2 million, highlighting an increase of 25.9% year over year.
Insulet’s Q2 Margin Performance
The gross profit in the reported quarter was $452.2 million, up 36.7% from the prior-year quarter’s figure. The gross margin of 69.7% expanded 193 basis points year over year.
Selling, general & administrative expenses rose 15.8% year over year to $257.7 million.
Research and development expenses jumped 36.2% year over year to $73.4 million.
The operating profit in the quarter totaled $121.1 million, up 122.2% from the year-ago reported actuals. The operating margin of 18.7% expanded 750 basis points year over year.
Insulet’s Cash Position
Insulet exited the second quarter of 2025 with cash and cash equivalents of $1.12 billion compared with $1.28 billion at the end of the first quarter.
Cumulative net cash provided by operating activities at the end of the second quarter was $260.3 million.
PODD’s 2025 Revenue Guidance
For 2025, the company now expects CER revenue growth to be 24%-27% (earlier 19%-22%). Insulet’s total Omnipod revenue growth is expected in the range of 25%-28% (previously 20% to 23%). The company expects Drug Delivery revenues to decline 30%-25% (earlier 35%-25%). The Zacks Consensus Estimate for the company’s 2025 revenues currently stands at $2.54 billion.
For the third quarter, Insulet projects revenue growth of 22%-25%. Total Omnipod revenues are also anticipated to grow 24-27%. Drug Delivery revenues are expected to decline 80%-75%. The consensus mark for the company’s third-quarter revenues currently stands at $666 million.
Our Take on Insulet’s Q2 Results
Insulet exited the second quarter of 2025 on a solid note, with both earnings and revenues beating estimates. The company grew new customer starts on a year-over-year and sequential basis in the United States for both type 1 and type 2, and internationally. U.S. Omnipod revenues benefited from a prior-year stocking dynamic and timing of rebates.
Internationally, growth in the U.K., Germany and France was particularly strong, in addition to other countries where Omnipod 5 was launched. The expansion of both margins in the quarter is highly encouraging. Insulet raised its full-year revenue guidance, making 2025 its tenth straight year of 20% or more growth on a constant-currency basis.
PODD’s Zacks Rank & Key Picks
PODD currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , GeneDx Holdings (WGS - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite’s 10.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 13.87%.
GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, exceeding the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%.
WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry’s 18.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 231.40%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a second-quarter 2025 adjusted EPS of 75 cents, which topped the Zacks Consensus Estimate by 4.2%.
BSX has a historical five-year earnings growth rate of 13.3% compared with the industry’s 2.7% growth. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 8.11%.